Limited Offer
Recent Developments in Anti-Inflammatory Therapy
- 1st Edition - February 17, 2023
- Editors: Parteek Prasher, Flavia Zacconi, Kamal Dua, Michael Rathbone, Jeffrey Withey
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 9 9 8 8 - 5
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 1 4 1 6 - 1
Advances in Anti-inflammatory Therapy explores the cutting-edge in anti-inflammation therapy in clear and concise language, with insights from academia and industry. Sections… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAdvances in Anti-inflammatory Therapy explores the cutting-edge in anti-inflammation therapy in clear and concise language, with insights from academia and industry. Sections cover key regulatory pathways that mediate acute and chronic inflammation and disease onset. Further chapters are devoted to advanced anti-inflammatory pharmaceuticals, including chemical moieties, pharmacophores, APIs, natural products, herbal therapies, molecular nanomedicine and advanced drug delivery vectors. Systematically planned chapters and illustrations enable potential readers to gain essential insights on the most recent advancements in the field.
Arranged with systematic chapters covering a broad range of inflammatory diseases, discussions on past, current and future therapeutics and advanced anti-inflammatory pharmaceuticals, this book will be useful to a wide range of researchers, especially medicinal chemists, drug design experts, and biological and translational researchers working in the field of inflammation.
- Identifies recent developments and current trends in anti-inflammation therapy
- Discusses advanced chemotherapeutics, SAR analysis of novel pharmacophores and natural products
- Outlines the pathophysiology of inflammatory pathways in the pathogenesis of disease onset, including strategies to counter these intricacies
- Contains a blend of editors from both academia and industry
2. Autoimmunity and inflammation
3. Regulatory Pathways of inflammation
4. Advanced nanomedicine-based therapeutics for targeting airway inflammatory diseases
5. Advanced Therapeutics for targeting gut inflammation
6. Advanced Therapeutics for renal inflammation
7. Advanced Therapeutics for targeting inflammatory arthritis
8. Advanced Therapeutics for targeting atherosclerosis
9. Targeting vascular inflammation in atherosclerosis with advanced therapeutics
10. Targeting cancer-inducing inflammation: Recent advancement and future prospects
11. Interplay between Gut Microbiota, Immune Homeostasis and Inflammatory Diseases
12. Advanced Drug delivery systems in inflammation
13. Advanced nanoparticles or nanoparticulate system for the treatment of Anti-inflammatory diseases
14. Theranostics in targeting inflammation in chronic diseases
15. Natural Product based anti-inflammatory agents
16. Mechanism of anti-inflammatory effects of various natural derived secondary metabolites
17. Herbal Bioactive Based Anti-Inflammatory Formulations for Topical Administration
18. Flavonoids in the treatment of inflammation
19. Heterocycles in the treatment of inflammation
20. In vivo models of understanding inflammation (In vivo methods for inflammation)
21. Clinical trials and Future Perspectives of anti-inflammatory agents
- No. of pages: 410
- Language: English
- Edition: 1
- Published: February 17, 2023
- Imprint: Academic Press
- Paperback ISBN: 9780323999885
- eBook ISBN: 9780323914161
PP
Parteek Prasher
FZ
Flavia Zacconi
KD
Kamal Dua
Dr. Kamal Dua is a Senior Lecturer in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over many years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua researches in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another, helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 80 research articles in peer-reviewed international journals and authored or co-authored four books. He is an active member of many national and international professional societies.
MR
Michael Rathbone
JW